期刊文献+

Super-ARMS法检测云南地区非小细胞肺癌患者外周血中EGFR突变及其临床意义 被引量:1

Detection of EGFR gene mutation in periphral blood of NSCLC patients in Yunnan by Super-ARMS and its clinical significance
原文传递
导出
摘要 目的:探讨使用超级扩增阻滞突变系统(Super-ARMS)法检测云南地区非小细胞肺癌(NSCLC)患者外周血中表皮生长因子受体(EGFR)基因突变与临床病理特征之间的关系。方法:收集2017年1月到2018年12月云南省肿瘤医院分子诊断分中心共检测的222例NSCLC患者外周血,以Super-ARMS法检测外周血浆中EGFR基因突变并分析其与临床病理特征的关系,同时分析影响EGFR突变的独立危险因素。结果:222例NSCLC患者的外周血浆中,EGFR基因突变阳性81例、突变率为36.5%,其中19号外显子缺失和L858R基因点突变最常见(占总突变的75.3%)。女性突变较男性高(45.9%vs 27.0%);<60岁患者突变率高于≥60岁患者(43.2%vs 28.8%)(均P<0.05或P<0.01);无吸烟史、无根治性手术史、腺癌、晚期和无化疗史患者EGFR基因突变率较高(43.9%vs 21.6%,39.2%vs 21.2%,43.9%vs 4.8%,39.7%vs 23.3%、44.0%vs 23.5%)(P<0.05或P<0.01)。多因素分析显示,年轻、无吸烟史、腺癌、无手术史是EGFR基因突变的独立危险因素(均P<0.01)。结论:在云南地区NSCLC患者外周血浆中,年龄<60岁、腺癌、不吸烟患者EGFR基因突变率更高,Super-ARMS法对肺癌患者外周血EGFR突变检测更灵敏。 Objective:To detect the mutation of epidermal growth factor receptor(EGFR) gene in peripheral blood of non-small cell lung cancer(NSCLC) patients in Yunnan area with Super-ARMS,and to explore its correlation with clinicopathological characteristics.Methods:A total of 222 blood samples from patients with NSCLC were collected between January 2017 to December 2018 in the Molecular Diagnostic Center of Yunnan Cancer Hospital.The EGFR gene mutation in peripheral blood samples was detected by SuperARMS,and the relationship between EGFR gene mutation and clinicopathological features was analyzed.Meanwhile,the independent risk factors influencing EFGR mutation were also analyzed.Results:In the peripheral blood of 222 NSCLC patients,there were 81 cases(36.5%) with EGFR gene mutation.Among them,exon 19 deletion and L858 R gene point mutation were the most common(75.3%of total mutation);female patients had a higher mutation rate than male patients(45.9% vs 27.0%);patients <60 years old had a higher incidence of mutation than patients≥60 years old(43.2% vs 28.8%)(P<0.05 or P<0.01);moreover,patients with no history of smoking,no history of radical surgery,adenocarcinoma,advanced stage and no history of chemotherapy had higher incidence of EGFR mutation(43.9% vs 21.6%,39.2% vs 21.2%,43.9% vs 4.8%,39.7% vs 23.3% and 44.0% vs 23.5%)(P<0.05 or P<0.01).Multivariate logistic analysis showed that young,no smoking history,adenocarcinoma and no surgical history were independent risk factors for EGFR gene mutation(all P<0.01).Conclusion:In the peripheral blood of patients with NSCLC in Yunnan,the mutation rate of EGFR gene is higher in patients with age<60 years old,adenocarcinoma and non-smoking.Super-ARMS method is more sensitive in the detection of EGFR mutation in peripheral blood of lung cancer patients.
作者 蔡静静 李鸿生 沈正海 马露瑶 李权 杜亚茜 刘俊熙 王晓雄 郭银金 周永春 CAI Jingjing;LI Hongsheng;SHEN Zhenghai;MA Luyao;LI Quan;DU Yaqian;LIU Junxi;WANG Xiaoxiong;GUO Yinjin;ZHOU Yongchun(Third Affiliated Hospital of Kunming Medical University,Yunnan Cancer Hospital,Yunnan Key Laboratory of Lung Cancer Research,Joint Laboratory of International Cooperation for Regional High-Incidence Tumors at High Altitude,Kunming 650118,Yunnan,China)
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 北大核心 2019年第12期1350-1355,共6页 Chinese Journal of Cancer Biotherapy
基金 国家自然科学基金资助项目(No.8186110513) 云南省科技计划资助项目(No.2017FA037,No.2017NS202)~~
关键词 超级扩增阻滞突变系统 非小细胞肺癌 表皮生长因子受体 DNA突变分析 super amplification refractory mutation system(Super-ARMS) non-small cell lung cancer(NSCLC) epidermal growth factor receptor(EGFR) DNA mutation
  • 相关文献

参考文献6

二级参考文献57

  • 1董强刚,韩宝惠,黄进肃,杨立民,黄建,赵春英,卢丽琴.176例非小细胞肺癌的EGFR基因突变分析[J].中华肿瘤杂志,2006,28(9):686-690. 被引量:53
  • 2Maria Sibilia, Renate Kroismayr, Beate M, et al. The epidermal growth factor receptor: from development to Tumorigenesis. Differentiation, 2007, 75(9): 770-787.
  • 3Lynch TJ, Bell DW, SordeUa R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness ofnon-small-cen lung cancer to gefitinib. N EnglJ Med, 2004, 350(21): 2129-2139.
  • 4Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science, 2004, 304(5676): 1497-1500.
  • 5Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implecations. Cancer Res, 2004, 64(24): 8919-8923.
  • 6Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer.J Natl Cancer Inst, 2005, 97(9): 643-655.
  • 7Han SW, Kim TY, Jeon YK, et al. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clio Cancer Res, 2006, 12(8): 2538-2544.
  • 8Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J. Cancer, 2006, 118(2): 257-262.
  • 9Mitsudomi T, Kosaka T, Endoh H, et al. Mutations oft_he epidermal growth factor receptor gene pridict prolonged survival after gefitinib treatment in patients with non-mall-cell lung cancer with postoperative recurrence. J Clin Oncol, 2005, 23 ( 11 ): 2513-2520.
  • 10Taioli E, Wynder EL. Re: Endocrine factors and adenocarcinoma of the lung in women.J Natl Cancer Inst, 1994, 86(11): 869-870.

共引文献96

同被引文献1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部